The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

18 Years to 80 Years (Adult, Older Adult)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Criteria

DISEASE CHARACTERISTICS:

Histologically confirmed diagnosis of one the following:

Stage II-IV gastric cancer

Stage IIC-IV ovarian cancer in first complete remission

CA 125 normal and stable*

Grade III anaplastic astrocytoma

Stage IV (M1) prostate adenocarcinoma

No small cell variations

No biochemical progression after definitive surgery, defined by the following:

Prostate-specific antigen more than 0.4 ng/mL which remains elevated on 2 additional measurements at least 2 weeks apart after prostatectomy

Three consecutive rises in PSA, each at least 1 month apart after definitive radiotherapy

Must be receiving androgen blockade

PSA less than 5 ng/mL and stable*

Documented EGFRvIII expression in primary tumor

Must have received prior surgery and or chemoradiotherapy for disease (except prostate cancer patients) NOTE: *Stable defined as no increase over 2 measurements at least 28 days apart with the last measurement within the past 28 days

PATIENT CHARACTERISTICS:

Age:

80 and under

Performance status:

Zubrod 0

Life expectancy:

Not specified

Hematopoietic:

WBC at least 3,000/mm^3

Platelet count at least 100,000/mm^3

Hemoglobin at least 10 g/dL

Hepatic:

SGOT no greater than 2.5 times upper limit of normal (ULN)

Alkaline phosphatase no greater than 2.5 times ULN

No hepatitis

Renal:

Not specified

Other:

No other malignancy in the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer in complete remission

No contraindication to receiving sargramostim (GM-CSF) or KLH-based vaccine products